Avalo Therapeutics, Inc.

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Ansbert Gadicke. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Ansbert Gadicke har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:ITOS / iTeos Therapeutics, Inc. 3.452.797
US:HOWL / Werewolf Therapeutics, Inc. 10% Owner 6.718.670
US:TRDA / Entrada Therapeutics, Inc. 10% Owner 4.381.062
US:TCRR / Tcr2 Therapeutics Inc Director, 10% Owner 0
US:CGEM / Cullinan Therapeutics, Inc. 10% Owner 595.489
US:ALVR / AlloVir, Inc. Director, 10% Owner 16.674.766
US:RPTX / Repare Therapeutics Inc. 10% Owner 3.882.485
US:HARP / Harpoon Therapeutics, Inc. 10% Owner 6.328.095
US:ONCR / Oncorus, Inc. 10% Owner 0
10% Owner 0
US:RYTM / Rhythm Pharmaceuticals, Inc. 10% Owner 0
US:RDUS / Radius Recycling, Inc. Director 27.500
Director 10.000
US:SNDX / Syndax Pharmaceuticals, Inc. 10% Owner 0
US:AVTX / Avalo Therapeutics, Inc. 10% Owner 0
US:TRIV / TriVascular Technologies, Inc. 10% Owner 37.369
US:PETX / Aratana Therapeutics, Inc. 10% Owner 2.751.048
US:EPZM / Epizyme Inc 10% Owner 2.413.819
US:CNAT / Conatus Pharmaceuticals Inc. 10% Owner 32.220
US:PCRX / Pacira BioSciences, Inc. 2.790.479
US:KBIO / KaloBios Pharmaceuticals, Inc. 10% Owner 0
US:SOMX / Somaxon Pharmaceuticals, Inc. 10% Owner 1.275.886
US:VSTM / Verastem, Inc. Director 12.500
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Ansbert Gadicke. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb AVTX / Avalo Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insidersalg AVTX / Avalo Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insiderkøb CGEM / Cullinan Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insidersalg CGEM / Cullinan Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2021-09-01 CGEM GADICKE ANSBERT 790 29,4700 790 29,4700 23.281 252 7.3100 -17.506 -75,19

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insiderkøb HOWL / Werewolf Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-05-04 HOWL GADICKE ANSBERT 245.000 16,0000 245.000 16,0000 3.920.000 59 20.3100 1.055.950 26,94

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

HOWL / Werewolf Therapeutics, Inc. Insider Trades
Insidersalg HOWL / Werewolf Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2025-03-27 HOWL GADICKE ANSBERT 4.386 1,0500 4.386 1,0500 4.605 11 0.6300 -1.842 -40,00

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

HOWL / Werewolf Therapeutics, Inc. Insider Trades
Insiderkøb HSTOQ / Histogen Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

HSTOQ / Histogen Inc. Insider Trades
Insidersalg HSTOQ / Histogen Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

HSTOQ / Histogen Inc. Insider Trades
Insiderkøb PCRX / Pacira BioSciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insidersalg PCRX / Pacira BioSciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PCRX / Pacira BioSciences, Inc. Insider Trades
Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-06-23 RPTX GADICKE ANSBERT 500.000 20,0000 500.000 20,0000 10.000.000 198 44.46 12.230.000 122,30

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2021-03-12 RPTX GADICKE ANSBERT 695.000 28,1800 695.000 28,1800 19.585.100 364 12.2100 -11.099.150 -56,67

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPTX / Repare Therapeutics Inc. Insider Trades
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2017-10-10 RYTM MPM BIOVENTURES V, L.P. 100.000 17,0000 100.000 17,0000 1.700.000 268 35.85 1.885.000 110,88

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insiderkøb SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insidersalg SNDX / Syndax Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insiderkøb TRDA / Entrada Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-11-02 TRDA MPM BioVentures 2014, L.P. 100.000 20,0000 100.000 20,0000 2.000.000 15 35 1.500.000 75,00

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRDA / Entrada Therapeutics, Inc. Insider Trades
Insidersalg TRDA / Entrada Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-12-11 TRDA MPM BioVentures 2014, L.P. 21.787 20,2300 21.787 20,2300 440.751 243 5.0200 -331.380 -75,19
2024-12-10 TRDA MPM BioVentures 2014, L.P. 22.935 20,7700 22.935 20,7700 476.360

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRDA / Entrada Therapeutics, Inc. Insider Trades
Insiderkøb VSTM / Verastem, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AVTX / Avalo Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2012-02-01 VSTM GADICKE ANSBERT 96.260 10,0000 8.022 120,0000 962.600 43 1729.44 12.909.238 1.341,08
2012-02-01 VSTM GADICKE ANSBERT 3.740 10,0000 312 120,0000 37.400

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

VSTM / Verastem, Inc. Insider Trades
Insidersalg VSTM / Verastem, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AVTX / Avalo Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

VSTM / Verastem, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Ansbert Gadicke som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-05-15 2025-05-13 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -1.031.931 3.452.797 -23,01 8,06 -8.317.364 27.829.544
2025-04-30 2025-03-27 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
S - Sale -4.386 6.718.670 -0,07 1,05 -4.605 7.054.604
2025-04-30 2025-03-27 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
X - Other 50.873 6.723.056 0,76 0,09 4.579 605.075
2024-12-12 2024-12-11 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale -21.787 4.381.062 -0,49 20,23 -440.751 88.628.884
2024-12-12 2024-12-10 4 TRDA Entrada Therapeutics, Inc.
Common Stock
S - Sale -22.935 4.402.849 -0,52 20,77 -476.360 91.447.174
2023-06-05 2023-06-01 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
J - Other -3.370.982 0 -100,00
2023-06-05 2023-06-01 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
J - Other -3.854.963 0 -100,00
2023-06-05 2023-06-01 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
J - Other -304.001 0 -100,00
2023-05-24 2023-05-22 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
S - Sale -70.170 304.001 -18,75 1,88 -131.920 571.522
2023-05-24 2023-05-22 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
X - Other 178.269 374.171 91,00 0,74 131.919 276.887
2023-02-10 2021-12-21 5 CGEM Cullinan Oncology, Inc.
Common Stock
M - Exercise 350.938 595.489 143,50 4,30 1.509.033 2.560.603
2022-08-01 2022-07-28 4 ALVR Allovir, Inc.
Common Stock
A - Award 3.253.796 16.674.766 24,24 4,61 15.000.000 76.870.671
2022-05-19 2022-05-17 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 27.500 27.500
2022-03-25 2021-09-16 4 CGEM Cullinan Oncology, Inc.
Stock Option (Right to Buy)
A - Award 7.800 7.800
2022-01-06 2022-01-05 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -30.347 4.484.728 -0,67 42,03 -1.275.484 188.493.118
2022-01-06 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -12.829 4.515.075 -0,28 46,47 -596.164 209.815.535
2022-01-06 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -11.318 4.527.904 -0,25 45,32 -512.932 205.204.609
2022-01-06 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -32.396 4.539.222 -0,71 43,20 -1.399.507 196.094.390
2022-01-06 2022-01-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale -158.579 4.571.618 -3,35 42,05 -6.668.247 192.236.537
2021-12-07 2021-12-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -2.499 4.730.197 -0,05 34,11 -85.241 161.347.020
2021-12-07 2021-12-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -30.059 4.732.696 -0,63 33,15 -996.456 156.888.872
2021-12-07 2021-12-06 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -100 4.762.755 0,00 35,04 -3.504 166.886.935
2021-12-07 2021-12-06 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -850 4.762.855 -0,02 34,08 -28.968 162.318.098
2021-12-07 2021-12-06 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.960 4.763.705 -0,04 33,57 -65.797 159.917.577
2021-12-07 2021-12-06 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -14.173 4.765.665 -0,30 32,35 -458.497 154.169.263
2021-12-07 2021-12-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -300 4.779.838 -0,01 36,26 -10.878 173.316.926
2021-12-07 2021-12-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -4.047 4.780.138 -0,08 35,44 -143.426 169.408.091
2021-12-07 2021-12-03 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -29.402 4.784.185 -0,61 34,68 -1.019.661 165.915.536
2021-12-02 2021-12-02 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -12.434 4.813.587 -0,26 34,83 -433.076 167.657.235
2021-12-02 2021-12-02 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -49.796 4.826.021 -1,02 33,74 -1.680.117 162.829.949
2021-12-02 2021-12-01 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.500 4.875.817 -0,03 35,34 -53.010 172.311.373
2021-12-02 2021-12-01 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -9.131 4.877.317 -0,19 34,61 -316.024 168.803.941
2021-12-02 2021-12-01 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -10.111 4.886.448 -0,21 33,82 -341.954 165.259.671
2021-12-02 2021-11-30 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -46.992 4.896.559 -0,95 35,19 -1.653.648 172.309.911
2021-12-02 2021-11-30 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -9.809 4.943.551 -0,20 34,62 -339.588 171.145.736
2021-11-30 2021-11-29 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -500 4.953.360 -0,01 35,37 -17.685 175.200.343
2021-11-30 2021-11-29 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -16.856 4.953.860 -0,34 34,46 -580.858 170.710.016
2021-11-30 2021-11-26 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -10.258 4.970.716 -0,21 36,03 -369.596 179.094.897
2021-11-30 2021-11-26 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -10.952 4.980.974 -0,22 35,49 -388.686 176.774.767
2021-11-24 2021-11-24 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -21.965 4.991.926 -0,44 37,02 -813.144 184.801.101
2021-11-24 2021-11-24 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -30.696 5.013.891 -0,61 36,05 -1.106.591 180.750.771
2021-11-24 2021-11-24 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -8.147 5.044.587 -0,16 35,20 -286.774 177.569.462
2021-11-24 2021-11-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -600 5.052.734 -0,01 36,50 -21.900 184.424.791
2021-11-24 2021-11-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -32.876 5.053.334 -0,65 36,21 -1.190.440 182.981.224
2021-11-24 2021-11-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -19.758 5.086.210 -0,39 37,81 -747.050 192.309.600
2021-11-24 2021-11-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -15.575 5.105.986 -0,30 37,16 -578.767 189.738.440
2021-11-24 2021-11-17 4 ITOS iTeos Therapeutics, Inc.
Common Stock
J - Other -15.671 5.121.543 -0,31
2021-11-04 2021-11-02 4 TRDA Entrada Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -3.683.241 0 -100,00
2021-11-04 2021-11-02 4 TRDA Entrada Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -27.617.675 0 -100,00
2021-11-04 2021-11-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
P - Purchase 100.000 4.425.784 2,31 20,00 2.000.000 88.515.680
2021-11-04 2021-11-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
C - Conversion 509.024 4.325.784 13,34
2021-11-04 2021-11-02 4 TRDA Entrada Therapeutics, Inc.
Common Stock
C - Conversion 3.816.760 3.816.760
2021-10-18 2021-10-18 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -10.320 5.137.214 -0,20 27,14 -280.085 139.423.988
2021-10-18 2021-10-15 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -3.413 5.147.534 -0,07 28,01 -95.598 144.182.427
2021-10-18 2021-10-15 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -14.882 5.150.947 -0,29 27,53 -409.701 141.805.571
2021-10-14 2021-10-14 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -45.719 5.165.829 -0,88 27,30 -1.248.129 141.027.132
2021-10-14 2021-10-13 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -35.023 5.211.548 -0,67 27,13 -950.174 141.389.297
2021-10-14 2021-10-12 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -14.260 5.246.571 -0,27 27,09 -386.303 142.129.608
2021-10-12 2021-10-11 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -81.684 5.260.831 -1,53 27,24 -2.225.072 143.305.036
2021-10-12 2021-10-08 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -3.400 5.342.515 -0,06 27,01 -91.834 144.301.330
2021-10-12 2021-10-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.922 5.345.915 -0,04 27,00 -51.894 144.339.705
2021-10-05 2021-10-04 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -34.659 5.347.837 -0,64 27,06 -937.873 144.712.469
2021-10-05 2021-10-01 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -11.471 5.382.496 -0,21 27,00 -309.717 145.327.392
2021-09-30 2021-09-30 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -3.836 5.393.967 -0,07 27,00 -103.572 145.637.109
2021-09-30 2021-09-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -32.154 5.397.803 -0,59 27,00 -868.158 145.740.681
2021-09-27 2021-09-27 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -19.455 5.429.957 -0,36 27,09 -527.036 147.097.535
2021-09-27 2021-09-24 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -8.221 5.449.412 -0,15 27,81 -228.626 151.548.148
2021-09-27 2021-09-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.200 5.457.633 -0,02 28,38 -34.056 154.887.625
2021-09-27 2021-09-23 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -60.600 5.458.833 -1,10 27,96 -1.694.376 152.628.971
2021-09-23 2021-09-22 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -23.921 5.519.433 -0,43 27,54 -658.784 152.005.185
2021-09-23 2021-09-21 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -32.858 5.543.354 -0,59 27,47 -902.609 152.275.934
2021-09-20 2021-09-16 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -3.124 7.648.268 -0,04 29,06 -90.783 222.258.668
2021-09-20 2021-09-16 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -432 244.551 -0,18 29,06 -12.554 7.106.652
2021-09-20 2021-09-20 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -22.930 5.576.212 -0,41 27,84 -638.371 155.241.742
2021-09-20 2021-09-20 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -17.743 5.599.142 -0,32 27,03 -479.593 151.344.808
2021-09-20 2021-09-17 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -76.473 5.616.885 -1,34 28,82 -2.203.952 161.878.626
2021-09-20 2021-09-16 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -35.565 5.693.358 -0,62 28,47 -1.012.536 162.089.902
2021-09-16 2021-09-15 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -6.425 7.651.392 -0,08 29,16 -187.353 223.114.591
2021-09-16 2021-09-15 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -888 244.983 -0,36 29,16 -25.894 7.143.704
2021-09-16 2021-09-14 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -7.106 7.657.817 -0,09 29,17 -207.282 223.378.522
2021-09-16 2021-09-14 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -982 245.871 -0,40 29,17 -28.645 7.172.057
2021-09-16 2021-09-15 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.659 5.728.923 -0,03 28,15 -46.701 161.269.182
2021-09-16 2021-09-15 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -38.677 5.730.582 -0,67 27,79 -1.074.834 159.252.874
2021-09-16 2021-09-14 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -6.063 5.769.259 -0,10 27,99 -169.703 161.481.559
2021-09-16 2021-09-14 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -30.018 5.775.322 -0,52 27,50 -825.495 158.821.355
2021-09-13 2021-09-13 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -3.595 7.664.923 -0,05 29,10 -104.614 223.049.259
2021-09-13 2021-09-13 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -497 246.853 -0,20 29,10 -14.463 7.183.422
2021-09-13 2021-09-10 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -5.931 7.668.518 -0,08 29,04 -172.236 222.693.763
2021-09-13 2021-09-10 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -820 247.350 -0,33 29,04 -23.813 7.183.044
2021-09-13 2021-09-09 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -13.727 7.674.449 -0,18 29,35 -402.887 225.245.078
2021-09-13 2021-09-09 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.898 248.170 -0,76 29,35 -55.706 7.283.790
2021-09-13 2021-09-13 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -35.785 5.805.340 -0,61 27,64 -989.097 160.459.598
2021-09-13 2021-09-10 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -11.330 5.841.125 -0,19 28,73 -325.511 167.815.521
2021-09-13 2021-09-10 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -11.313 5.852.455 -0,19 27,86 -315.180 163.049.396
2021-09-13 2021-09-09 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -38.028 5.863.768 -0,64 28,97 -1.101.671 169.873.359
2021-09-08 2021-09-08 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -10.842 7.688.176 -0,14 29,11 -315.611 223.802.803
2021-09-08 2021-09-08 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.499 250.068 -0,60 29,11 -43.636 7.279.479
2021-09-08 2021-09-07 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -25.067 7.699.018 -0,32 29,04 -727.946 223.579.483
2021-09-08 2021-09-07 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -3.465 251.567 -1,36 29,04 -100.624 7.305.506
2021-09-08 2021-09-03 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -12.731 7.724.085 -0,16 29,60 -376.838 228.632.916
2021-09-08 2021-09-03 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.760 255.032 -0,69 29,60 -52.096 7.548.947
2021-09-08 2021-09-08 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.573 5.901.796 -0,03 29,10 -45.774 171.742.264
2021-09-08 2021-09-08 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -18.663 5.903.369 -0,32 28,61 -533.948 168.895.387
2021-09-08 2021-09-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
J - Other -31.340 5.922.032 -0,53
2021-09-08 2021-09-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -50.996 5.953.372 -0,85 29,18 -1.488.063 173.719.395
2021-09-02 2021-09-02 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -15.757 7.736.816 -0,20 29,46 -464.201 227.926.599
2021-09-02 2021-09-02 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -2.178 256.792 -0,84 29,46 -64.164 7.565.092
2021-09-02 2021-09-01 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -5.714 7.752.573 -0,07 29,47 -168.392 228.468.326
2021-09-02 2021-09-01 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale -790 258.970 -0,30 29,47 -23.281 7.631.846
2021-09-02 2021-08-31 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.553 7.758.287 -0,02 30,14 -46.807 233.834.770
2021-09-02 2021-08-31 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -215 259.760 -0,08 30,14 -6.480 7.829.166
2021-09-02 2021-08-31 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.285 7.759.840 -0,02 29,43 -37.818 228.372.091
2021-09-02 2021-08-31 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -177 259.975 -0,07 29,43 -5.209 7.651.064
2021-08-31 2021-08-30 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -31.001 7.761.125 -0,40 29,30 -908.329 227.400.962
2021-08-31 2021-08-30 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -4.285 260.152 -1,62 29,30 -125.550 7.622.454
2021-08-31 2021-08-27 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -13.357 7.792.126 -0,17 29,09 -388.555 226.672.945
2021-08-31 2021-08-27 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.846 264.437 -0,69 29,09 -53.700 7.692.472
2021-08-25 2021-08-25 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -1.713 7.805.483 -0,02 29,09 -49.831 227.061.500
2021-08-25 2021-08-25 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -237 266.283 -0,09 29,09 -6.894 7.746.172
2021-08-25 2021-08-24 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -50.882 7.807.196 -0,65 29,48 -1.500.001 230.156.138
2021-08-25 2021-08-24 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -7.025 266.520 -2,57 29,48 -207.097 7.857.010
2021-08-25 2021-08-23 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -53.359 7.858.018 -0,67 29,11 -1.553.280 228.746.904
2021-08-25 2021-08-23 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -7.376 273.545 -2,63 29,11 -214.715 7.962.895
2021-08-12 2021-08-11 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -2.510 7.911.377 -0,03 29,05 -72.916 229.825.502
2021-08-12 2021-08-11 4 CGEM Cullinan Oncology, Inc.
Common Stock
S - Sale X -347 280.921 -0,12 29,05 -10.080 8.160.755
2021-07-13 2021-07-12 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -711 3.882.485 -0,02 34,10 -24.245 132.392.738
2021-07-13 2021-07-12 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -57.301 3.883.196 -1,45 33,58 -1.924.168 130.397.722
2021-07-13 2021-07-09 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -4.067 3.940.497 -0,10 33,06 -134.455 130.272.831
2021-06-30 2021-06-29 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -2.700 3.944.564 -0,07 33,29 -89.883 131.314.536
2021-06-30 2021-06-28 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -2.700 3.947.264 -0,07 34,82 -94.014 137.443.732
2021-06-30 2021-06-28 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -13.800 3.949.964 -0,35 34,06 -470.028 134.535.774
2021-06-28 2021-06-25 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -22.567 3.963.764 -0,57 33,51 -756.220 132.825.732
2021-06-28 2021-06-24 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -6.121 3.986.331 -0,15 33,53 -205.237 133.661.678
2021-06-23 2021-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -1.410 3.992.452 -0,04 32,98 -46.502 131.671.067
2021-06-23 2021-06-22 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -429 3.993.862 -0,01 34,09 -14.625 136.150.756
2021-06-23 2021-06-22 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -3.371 3.994.291 -0,08 33,36 -112.457 133.249.548
2021-06-23 2021-06-21 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -31.788 3.997.662 -0,79 34,63 -1.100.818 138.439.035
2021-06-23 2021-06-21 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -5.800 4.029.450 -0,14 33,80 -196.040 136.195.410
2021-06-21 2021-06-18 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -3.199 4.035.250 -0,08 34,03 -108.862 137.319.558
2021-06-21 2021-06-18 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -5.801 4.038.449 -0,14 33,46 -194.101 135.126.504
2021-06-21 2021-06-17 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -1.708 4.044.250 -0,04 34,12 -58.277 137.989.810
2021-06-21 2021-06-17 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -30.810 4.045.958 -0,76 33,78 -1.040.762 136.672.461
2021-06-16 2021-06-16 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -4.227 4.076.768 -0,10 33,33 -140.886 135.878.677
2021-06-16 2021-06-14 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -2.000 4.080.995 -0,05 33,09 -66.180 135.040.125
2021-06-10 2021-06-09 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -24.368 4.082.995 -0,59 34,79 -847.763 142.047.396
2021-06-10 2021-06-09 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -10.862 4.107.363 -0,26 34,42 -373.870 141.375.434
2021-06-10 2021-06-08 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -17.155 4.118.225 -0,41 33,41 -573.149 137.589.897
2021-06-10 2021-06-08 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -9.045 4.135.380 -0,22 32,80 -296.676 135.640.464
2021-06-07 2021-06-07 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -19.017 4.144.425 -0,46 32,96 -626.800 136.600.248
2021-06-07 2021-06-07 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -1.700 4.163.442 -0,04 32,25 -54.825 134.271.004
2021-06-07 2021-06-07 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -2.400 4.165.142 -0,06 30,74 -73.776 128.036.465
2021-06-07 2021-06-04 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -4.694 4.167.542 -0,11 31,28 -146.828 130.360.714
2021-06-07 2021-06-04 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -8.042 4.172.236 -0,19 30,80 -247.694 128.504.869
2021-06-07 2021-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -22.296 4.180.278 -0,53 31,92 -711.688 133.434.474
2021-06-02 2021-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -297 4.202.574 -0,01 32,42 -9.629 136.247.449
2021-06-02 2021-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -5.918 4.202.871 -0,14 31,83 -188.370 133.777.384
2021-06-02 2021-06-01 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -15.141 4.208.789 -0,36 32,50 -492.082 136.785.642
2021-06-02 2021-05-28 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -16.742 4.223.930 -0,39 32,67 -546.961 137.995.793
2021-06-02 2021-06-02 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -25.118 6.328.095 -0,40 20,50 -514.919 129.725.948
2021-06-02 2021-06-01 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -18.491 6.353.213 -0,29 20,44 -377.956 129.859.674
2021-06-02 2021-05-28 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -100 6.371.704 0,00 22,60 -2.260 144.000.510
2021-06-02 2021-05-28 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -3.100 6.371.804 -0,05 21,92 -67.952 139.669.944
2021-06-02 2021-05-28 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10.685 6.374.904 -0,17 20,88 -223.103 133.107.996
2021-05-27 2021-05-25 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 22.500 22.500
2021-05-27 2021-05-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13.961 6.385.589 -0,22 20,26 -282.850 129.372.033
2021-05-27 2021-05-26 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -3.198 6.399.550 -0,05 20,04 -64.088 128.246.982
2021-05-27 2021-05-27 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -3.624 4.240.672 -0,09 33,16 -120.172 140.620.684
2021-05-27 2021-05-27 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -4.327 4.244.296 -0,10 32,81 -141.969 139.255.352
2021-05-27 2021-05-26 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -1.704 4.248.623 -0,04 33,01 -56.249 140.247.045
2021-05-27 2021-05-26 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -22.332 4.250.327 -0,52 32,74 -731.150 139.155.706
2021-05-27 2021-05-25 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -100 4.272.659 0,00 33,59 -3.359 143.518.616
2021-05-27 2021-05-25 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -6.472 4.272.759 -0,15 32,87 -212.735 140.445.588
2021-05-24 2021-05-24 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -5.000 6.402.748 -0,08 20,12 -100.600 128.823.290
2021-05-24 2021-05-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10.907 6.407.748 -0,17 20,21 -220.430 129.500.587
2021-05-24 2021-05-24 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -18.653 4.279.231 -0,43 34,28 -639.425 146.692.039
2021-05-24 2021-05-24 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -3.547 4.297.884 -0,08 33,30 -118.115 143.119.537
2021-05-24 2021-05-21 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -302.669 4.301.431 -6,57 34,80 -10.532.881 149.689.799
2021-05-20 2021-05-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -11.713 6.418.655 -0,18 20,34 -238.242 130.555.443
2021-05-20 2021-05-19 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -17.833 6.430.368 -0,28 20,39 -363.615 131.115.204
2021-05-20 2021-05-18 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -18.402 6.448.201 -0,28 20,67 -380.369 133.284.315
2021-05-20 2021-05-20 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -600 4.604.100 -0,01 35,19 -21.114 162.018.279
2021-05-20 2021-05-20 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -9.357 4.604.700 -0,20 34,66 -324.314 159.598.902
2021-05-20 2021-05-19 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -4.400 4.614.057 -0,10 35,00 -154.000 161.491.995
2021-05-20 2021-05-19 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -9.143 4.618.457 -0,20 34,23 -312.965 158.089.783
2021-05-20 2021-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other X -21.834 4.627.600 -0,47
2021-05-20 2021-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -90 4.649.434 0,00 35,14 -3.163 163.381.111
2021-05-20 2021-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -8.541 4.649.524 -0,18 34,61 -295.604 160.920.026
2021-05-20 2021-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale X -14.773 4.658.065 -0,32 33,90 -500.805 157.908.404
2021-05-17 2021-05-17 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -4.666 6.466.603 -0,07 20,07 -93.647 129.784.722
2021-05-17 2021-05-14 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -6.900 6.471.269 -0,11 20,04 -138.276 129.684.231
2021-05-17 2021-05-13 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -4.855 6.478.169 -0,07 20,06 -97.391 129.952.070
2021-05-12 2021-05-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -29.684 6.483.024 -0,46 20,53 -609.413 133.096.483
2021-05-12 2021-05-11 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -7.672 6.512.708 -0,12 21,51 -165.025 140.088.349
2021-05-12 2021-05-11 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13.773 6.520.380 -0,21 20,96 -288.682 136.667.165
2021-05-12 2021-05-10 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -411 6.534.153 -0,01 22,46 -9.231 146.757.076
2021-05-12 2021-05-10 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -16.722 6.534.564 -0,26 21,78 -364.205 142.322.804
2021-05-06 2021-05-05 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -59 6.551.286 0,00 23,09 -1.362 151.269.194
2021-05-06 2021-05-05 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10.113 6.551.345 -0,15 22,52 -227.745 147.536.289
2021-05-06 2021-05-04 4 HOWL Werewolf Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -12.899.925 0 -100,00
2021-05-06 2021-05-04 4 HOWL Werewolf Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -38.817.998 0 -100,00
2021-05-06 2021-05-04 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
P - Purchase 245.000 6.672.183 3,81 16,00 3.920.000 106.754.928
2021-05-06 2021-05-04 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
C - Conversion 1.488.033 6.427.183 30,13
2021-05-06 2021-05-04 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
C - Conversion 4.477.742 4.939.150 970,45
2021-05-04 2021-05-04 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -3.500 6.561.458 -0,05 23,33 -81.655 153.078.815
2021-05-04 2021-05-04 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -26.230 6.564.958 -0,40 23,03 -604.077 151.190.983
2021-05-04 2021-05-03 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -4.401 6.591.188 -0,07 23,45 -103.203 154.563.359
2021-05-04 2021-05-03 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -26.365 6.595.589 -0,40 23,03 -607.186 151.896.415
2021-05-04 2021-04-30 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -268.023 6.621.954 -3,89 22,35 -5.990.314 148.000.672
2021-04-29 3 HOWL Werewolf Therapeutics, Inc.
Common Stock
461.408
2021-04-29 2021-04-29 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -21.781 6.889.977 -0,32 22,54 -490.944 155.300.082
2021-04-29 2021-04-29 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -45.511 6.911.758 -0,65 22,02 -1.002.152 152.196.911
2021-04-29 2021-04-28 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -36.803 6.957.269 -0,53 22,01 -810.034 153.129.491
2021-04-29 2021-04-28 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -14.219 6.994.072 -0,20 21,64 -307.699 151.351.718
2021-04-29 2021-04-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -8.328 7.008.291 -0,12 21,26 -177.053 148.996.267
2021-04-29 2021-04-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -3.501 7.016.619 -0,05 20,99 -73.486 147.278.833
2021-04-22 2021-04-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -555 7.020.120 -0,01 19,48 -10.811 136.751.938
2021-04-22 2021-04-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -8.417 7.020.675 -0,12 18,94 -159.418 132.971.584
2021-04-20 2021-04-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -834 7.029.092 -0,01 19,09 -15.921 134.185.366
2021-04-20 2021-04-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -21.415 7.029.926 -0,30 18,70 -400.460 131.459.616
2021-04-20 2021-04-19 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -100 7.051.341 0,00 20,08 -2.008 141.590.927
2021-04-20 2021-04-19 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -9.956 7.051.441 -0,14 19,29 -192.051 136.022.297
2021-04-20 2021-04-16 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -300 7.061.397 0,00 20,56 -6.168 145.182.322
2021-04-20 2021-04-16 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -5.547 7.061.697 -0,08 19,82 -109.942 139.962.835
2021-04-15 2021-04-15 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -8.696 7.067.244 -0,12 20,49 -178.181 144.807.830
2021-04-15 2021-04-14 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -12.806 7.075.940 -0,18 20,83 -266.749 147.391.830
2021-04-15 2021-04-14 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1.000 7.088.746 -0,01 20,06 -20.060 142.200.245
2021-04-15 2021-04-13 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -2.362 7.089.746 -0,03 20,08 -47.429 142.362.100
2021-04-15 2021-04-13 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13.692 7.092.108 -0,19 19,35 -264.940 137.232.290
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -400 7.105.800 -0,01 22,68 -9.072 161.159.544
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -6.700 7.106.200 -0,09 21,52 -144.184 152.925.424
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13.528 7.112.900 -0,19 20,72 -280.300 147.379.288
2021-04-13 2021-04-09 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10.300 7.126.428 -0,14 23,67 -243.801 168.682.551
2021-04-13 2021-04-09 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -200 6.004.368 0,00 29,99 -5.998 180.070.996
2021-04-09 2021-04-08 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -414 6.004.568 -0,01 31,01 -12.838 186.201.654
2021-04-09 2021-04-08 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -31.890 6.004.982 -0,53 30,51 -972.964 183.212.001
2021-04-09 2021-04-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
J - Other -15.670 6.036.872 -0,26
2021-04-09 2021-04-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -1.300 6.052.542 -0,02 33,84 -43.992 204.818.021
2021-04-09 2021-04-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -3.083 6.053.842 -0,05 32,84 -101.246 198.808.171
2021-04-09 2021-04-07 4 ITOS iTeos Therapeutics, Inc.
Common Stock
S - Sale X -5.295 6.056.925 -0,09 32,07 -169.811 194.245.585
2021-03-15 2021-03-15 4 RPTX Repare Therapeutics Inc.
Common Shares
J - Other 24.271 4.672.838 0,52
2021-03-15 2021-03-12 4 RPTX Repare Therapeutics Inc.
Common Shares
S - Sale -695.000 4.697.109 -12,89 28,18 -19.585.100 132.364.532
2021-02-12 2021-02-10 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -183.051 3.238.306 -5,35 20,00 -3.661.020 64.766.120
2021-02-09 2021-02-09 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -9.400 3.421.357 -0,27 20,25 -190.350 69.282.479
2021-02-09 2021-02-08 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -72.128 3.430.757 -2,06 20,04 -1.445.445 68.752.370
2021-02-09 2021-02-05 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10.172 3.502.885 -0,29 20,01 -203.542 70.092.729
2021-02-04 2021-02-04 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -29.730 3.513.057 -0,84 20,37 -605.600 71.560.971
2021-02-04 2021-02-03 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -41.922 3.542.787 -1,17 20,21 -847.244 71.599.725
2021-02-04 2021-02-02 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -48.421 3.584.709 -1,33 20,13 -974.715 72.160.192
2021-01-27 2021-01-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -706.825 3.633.130 -16,29 20,00 -14.136.500 72.662.600
2021-01-27 2021-01-26 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1.363 4.339.955 -0,03 21,08 -28.732 91.486.251
2021-01-27 2021-01-25 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13.006 4.341.318 -0,30 21,23 -276.117 92.166.181
2021-01-22 2021-01-22 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -24.695 4.354.324 -0,56 21,72 -536.375 94.575.917
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -200 4.379.019 0,00 23,77 -4.754 104.089.282
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -4.887 4.379.219 -0,11 22,61 -110.495 99.014.142
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -20.979 4.384.106 -0,48 22,11 -463.846 96.932.584
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
J - Other X -101.646 4.405.085 -2,26
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -2.000 4.506.731 -0,04 24,71 -49.420 111.361.323
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -15.694 4.508.731 -0,35 23,95 -375.871 107.984.107
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Series C Convertible Preferred Stock
C - Conversion -649.030 0 -100,00
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Series B Convertible Preferred Stock
C - Conversion -2.276.692 0 -100,00
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Series A Convertible Preferred Stock
C - Conversion -3.551.640 0 -100,00
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Series Seed Convertible Preferred Stock
C - Conversion -1.136.525 0 -100,00
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Common Stock
P - Purchase 300.000 7.913.887 3,94 21,00 6.300.000 166.191.627
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Common Stock
C - Conversion 649.030 7.613.887 9,32
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Common Stock
C - Conversion 2.276.692 6.964.857 48,56
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Common Stock
C - Conversion 3.551.640 4.688.165 312,50
2021-01-14 2021-01-12 4 CGEM Cullinan Management, Inc.
Common Stock
C - Conversion 1.136.525 1.136.525
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Stock Option (Right to Buy)
J - Other 88.824 88.824
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Stock Option (Right to Buy)
J - Other 262.114 262.114
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Series C Convertible Preferred Stock
J - Other 649.030 649.030
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Series B Convertible Preferred Stock
J - Other 2.276.692 2.276.692
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Series A Convertible Preferred Stock
J - Other 3.551.640 3.551.640
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Series Seed Convertible Preferred Stock
J - Other 1.136.525 1.136.525
2021-01-14 2021-01-07 4 CGEM Cullinan Management, Inc.
Common Stock
J - Other 281.268 281.268
2021-01-07 3 CGEM Cullinan Management, Inc.
Common Stock
281.268
2020-10-21 2020-07-23 4/A ITOS iTeos Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16.608 0 -100,00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series B Preferred Stock
C - Conversion 700.453 0 -100,00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series B Preferred Stock
C - Conversion 775.975 0 -100,00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series A-1 Preferred Stock
C - Conversion 1.525.348 0 -100,00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series A-1 Preferred Stock
C - Conversion 1.783.879 0 -100,00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
P - Purchase 151.224 2.377.025 6,79 15,00 2.268.360 35.655.375
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
P - Purchase 173.776 2.849.453 6,49 15,00 2.606.640 42.741.795
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 700.453 2.225.801 45,92
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 775.975 2.675.677 40,85
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 1.525.348 1.525.348
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 1.783.879 1.899.702 1.540,18
2020-10-01 3 ONCR Oncorus, Inc.
Common Stock
115.823
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -26.176 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -70.492 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.326.313 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -275.932 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -743.076 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -13.980.992 0 -100,00
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Common Stock
C - Conversion 91.081 91.081
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Common Stock
C - Conversion 245.279 245.279
2020-09-23 2020-09-21 4 DYN Dyne Therapeutics, Inc.
Common Stock
C - Conversion 4.614.943 4.614.943
2020-08-05 2020-08-03 4 ALVR Allovir, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -20.000.000 0 -100,00
2020-08-05 2020-08-03 4 ALVR Allovir, Inc.
Common Stock
C - Conversion 13.420.970 13.420.970
2020-07-31 2020-07-29 4 ALVR Allovir, Inc.
Stock Option (Right to Buy)
A - Award 22.500 22.500
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -2.600.628 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -29.440 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -79.281 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -1.491.666 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -81.295 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -157.529 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B-2 Preferred Stock
C - Conversion -2.361.805 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -4.211.330 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -47.674 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -128.384 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -2.415.530 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -131.645 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -255.094 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -3.824.591 0 -100,00
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 160.000 2.355.557 7,29 19,00 3.040.000 44.755.583
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 1.121 25.974 4,51 19,00 21.299 493.506
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 3.020 69.951 4,51 19,00 57.380 1.329.069
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 56.814 1.316.139 4,51 19,00 1.079.466 25.006.641
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 3.096 71.727 4,51 19,00 58.824 1.362.813
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 5.994 138.985 4,51 19,00 113.886 2.640.715
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
P - Purchase 89.955 2.083.887 4,51 19,00 1.709.145 39.593.853
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 797.983 2.195.557 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 9.033 24.853 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 24.326 66.931 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 457.706 1.259.325 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 24.944 68.381 57,43
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 48.336 132.991 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 724.702 1.993.932 57,10
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 1.397.574 1.397.574
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 15.820 15.820
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 42.605 42.605
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 801.619 801.619
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 43.687 43.687
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 84.655 84.655
2020-07-30 2020-07-28 4 ITOS iTeos Therapeutics, Inc.
Common Stock
C - Conversion 1.269.230 1.269.230
2020-07-29 3 ALVR Allovir, Inc.
Common Stock
60.394
2020-07-29 3 ALVR Allovir, Inc.
Common Stock
60.394
2020-07-29 3 ALVR Allovir, Inc.
Common Stock
60.394
2020-07-24 2020-07-23 4 ITOS iTeos Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 16.608 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class B Preferred Shares
C - Conversion -1.288.948 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Class A Preferred Shares
C - Conversion -3.603.161 0 -100,00
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
P - Purchase 500.000 5.392.109 10,22 20,00 10.000.000 107.842.180
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 1.288.948 4.892.109 35,77
2020-06-25 2020-06-23 4 RPTX Repare Therapeutics Inc.
Common Shares
C - Conversion 3.603.161 3.603.161
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -1.750.000 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -217.500 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -1.586.623 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -105.825 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -32.500 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -57.552 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -15.000.000 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -2.174.998 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -13.599.621 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -907.073 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -325.002 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -493.306 0 -100,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
P - Purchase 1.373.333 1.569.235 701,03 15,00 20.599.995 23.538.525
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 282.540 2.704.315 11,67
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 35.115 386.270 10,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 256.163 2.451.844 11,67
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 17.085 163.532 11,67
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 5.247 57.716 10,00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 9.291 88.935 11,67
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 2.421.775 2.421.775
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 351.155 351.155
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 2.195.681 2.195.681
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 146.447 146.447
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 52.469 52.469
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 79.644 79.644
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -101.675 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -152.514 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -50.837 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -171.579 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -57.192 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -25.418 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -835.705 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -3.157.506 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -3.050.329 0 -100,00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
P - Purchase 500.000 8.422.847 6,31 14,00 7.000.000 117.919.858
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale -1.971 7.922.847 -0,02 14,00 -27.594 110.919.858
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
X - Other 559.215 7.924.818 7,59 0,05 27.513 389.901
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 835.705 7.365.603 12,80
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 3.157.506 6.529.898 93,63
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 3.050.329 3.372.392 947,12
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391.804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391.804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391.804
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644.126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644.126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644.126
2017-10-11 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A-1 Junior Preferred Stock
C - Conversion -15.887.703 0 -100,00
2017-10-11 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Series A Preferred Stock
C - Conversion -7.651.831 0 -100,00
2017-10-11 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
P - Purchase 100.000 2.696.392 3,85 17,00 1.700.000 45.838.664
2017-10-11 2017-10-10 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
C - Conversion 2.567.014 2.596.392 8.737,88
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-10-04 3 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
58.756
2017-02-22 2017-02-17 4 RDUS Radius Health, Inc.
Stock Option (Right to Buy)
A - Award 27.500 27.500
2016-09-29 2016-09-27 4 RDUS Radius Health, Inc.
Common Stock
J - Other -1.943.751 3.887.502 -33,33
2016-06-13 2016-06-09 4 CHMA CHIASMA, INC
Stock Option (Right to Buy)
A - Award 10.000 10.000
2016-06-02 2016-05-24 4 RDUS Radius Health, Inc.
Stock Option (Right to Buy)
A - Award 27.500 27.500
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock
C - Conversion -312.085 0 -100,00
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock
C - Conversion -718.396 0 -100,00
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock
C - Conversion -1.138.210 0 -100,00
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
C - Conversion 312.085 2.168.691 16,81
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
C - Conversion 718.396 1.856.606 63,12
2016-03-09 2016-03-08 4 SNDX Syndax Pharmaceuticals Inc
Common Stock
C - Conversion 1.138.210 1.138.210
2016-02-12 2016-02-10 4 RDUS Radius Health, Inc.
Stock Option (Right to Buy)
A - Award 27.500 27.500
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Series B Convertible Preferred Stock
C - Conversion -16.672.224 0 -100,00
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Common Stock
C - Conversion 595.436 595.436
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Series E Preferred Stock
C - Conversion -13.000.000 0 -100,00
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Series D' Preferred Stock
C - Conversion -16.066.669 0 -100,00
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Series C' Preferred Stock
C - Conversion -22.721.988 0 -100,00
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Series B-1' Preferred Stock
C - Conversion -95.225 0 -100,00
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Common Stock
C - Conversion 1.423.566 5.681.544 33,43
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Common Stock
C - Conversion 1.759.381 4.257.978 70,41
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Common Stock
C - Conversion 2.488.171 2.498.597 23.865,06
2015-07-21 2015-07-21 4 CHMA CHIASMA, INC
Common Stock
C - Conversion 10.426 10.426
2015-05-26 2015-05-07 4 RDUS Radius Health, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2014-12-19 2014-12-17 4 RDUS Radius Health, Inc.
Stock Option (Right to Buy)
A - Award 30.000 30.000
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -184.242 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -114.537 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -71.638 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -859 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -3.511 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -4.346 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -1.468 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -1.340 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -5.477 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -6.779 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -2.291 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -3.752 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -15.327 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -18.975 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -6.414 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -44.395 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -181.364 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -224.528 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -75.899 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -2.985 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -12.194 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -15.096 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Series B Convertible Preferred Stock
C - Conversion -5.103 0 -100,00
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 2.141.547 2.141.547
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 59.445 59.445
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 92.734 92.734
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 259.567 259.567
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 3.071.454 3.071.454
2014-06-10 2014-06-06 4 RDUS Radius Health, Inc.
Common Stock
C - Conversion 206.506 206.506
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Warrant to Purchase Common Stock (Right to Buy)
C - Conversion 37.369 37.369
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Warrant to Purchase Series D Preferred Stock (Right to Buy)
C - Conversion -1.516.122 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series E Convertible Preferred Stock
C - Conversion -10.266.940 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series D Convertible Preferred Stock
C - Conversion -15.400.411 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series C Convertible Preferred Stock
C - Conversion -2.947.605 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series B Convertible Preferred Stock
C - Conversion -6.000.000 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Series A Convertible Preferred Stock
C - Conversion -20.757.635 0 -100,00
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 253.066 1.776.692 16,61
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 379.599 1.523.626 33,18
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 114.942 1.144.027 11,17
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 230.756 1.029.085 28,90
2014-04-23 2014-04-22 4 TRIV TriVascular Technologies, Inc.
Common Stock
C - Conversion 798.329 798.329
2014-03-12 2014-03-10 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
S - Sale -600.000 2.751.048 -17,90 20,02 -12.012.000 55.075.981
2014-03-11 2014-03-07 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
S - Sale -26.713 0 -100,00 20,16 -538.534
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 37.117 37.117
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 12.247 12.393 8.388,36
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 15.310 17.937 582,79
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 20.876 22.767 1.103,97
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 20.876 22.767 1.103,97
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other 20.876 38.386 119,22
2014-03-05 2014-03-03 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
J - Other -1.000.000 3.351.048 -22,98
2014-02-11 2014-02-10 4 EPZM Epizyme, Inc.
Common Stock
S - Sale -466.666 2.413.819 -16,20 29,25 -13.649.980 70.604.206
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Common Stock (Right to Buy)
C - Conversion 32.220 32.220
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Warrant to Purchase Series B Preferred Stock (Right to Buy)
C - Conversion -265.837 0 -100,00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Series B Convertible Preferred Stock
C - Conversion -8.333.334 0 -100,00
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
P - Purchase 165.265 1.192.080 16,09 11,00 1.817.915 13.112.880
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
J - Other 16.716 1.026.815 1,65 11,00 183.876 11.294.965
2013-08-01 2013-07-30 4 CNAT Conatus Pharmaceuticals Inc
Common Stock
C - Conversion 1.010.099 1.010.099
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Series C Preferred Stock
C - Conversion -375.000 0 -100,00
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Series B Preferred Stock
C - Conversion -1.333.333 0 -100,00
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Series A Preferred Stock
C - Conversion -4.000.000 0 -100,00
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
P - Purchase 500.000 4.351.050 12,98 6,00 3.000.000 26.106.300
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
C - Conversion 225.631 3.851.050 6,22
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
C - Conversion 802.246 3.625.419 28,42
2013-07-02 2013-07-02 4 PETX ARATANA THERAPEUTICS, INC.
Common Stock
C - Conversion 2.406.739 2.823.173 577,94
2013-06-26 3 PETX ARATANA THERAPEUTICS, INC.
Common Stock
180.505
2013-06-06 2013-06-05 4 EPZM Epizyme, Inc.
Series B Preferred Stock
C - Conversion -1.176.472 0 -100,00
2013-06-06 2013-06-05 4 EPZM Epizyme, Inc.
Series A Preferred Stock
C - Conversion -6.930.000 0 -100,00
2013-06-06 2013-06-05 4 EPZM Epizyme, Inc.
Common Stock
C - Conversion 392.156 2.880.485 15,76
2013-06-06 2013-06-05 4 EPZM Epizyme, Inc.
Common Stock
C - Conversion 2.309.998 2.488.329 1.295,34
2013-05-30 3 EPZM Epizyme, Inc.
Common Stock
178.331
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 179.095 179.095
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 71.638 71.638 61,42 4.400.006 4.400.006
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 3.670 3.670
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 1.468 1.468 61,42 90.165 90.165
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 5.728 5.728
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 2.291 2.291 61,42 140.713 140.713
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 16.035 16.035
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 6.414 6.414 61,42 393.948 393.948
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 189.748 189.748
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 75.899 75.899 61,42 4.661.717 4.661.717
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Common Stock Warrant
A - Award 12.758 12.758
2013-04-25 2013-04-23 4 NONE Radius Health, Inc.
Series B Convertible Preferred Stock
A - Award 5.103 5.103 61,42 313.426 313.426
2013-03-13 2013-03-11 4 PCRX Pacira Pharmaceuticals, Inc.
Common Stock
S - Sale -500.000 2.790.479 -15,20 27,86 -13.930.000 77.742.745
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Series D Preferred Stock
C - Conversion -275.539 0 -100,00
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Series C Preferred Stock
C - Conversion -337.622 0 -100,00
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Series B-2 Preferred Stock
C - Conversion -1.949.879 0 -100,00
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Common Stock
C - Conversion 313.527 2.632.928 13,52
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Common Stock
C - Conversion 369.522 2.319.401 18,95
2013-02-07 2013-02-05 4 KBIO KALOBIOS PHARMACEUTICALS INC
Common Stock
C - Conversion 1.949.879 1.949.879
2012-07-10 2012-07-09 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -1.624.574 1.275.886 -56,01 0,31 -498.744 391.697
2012-07-10 2012-07-06 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -671.217 2.900.460 -18,79 0,29 -195.324 844.034
2012-07-05 2012-07-03 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -98.210 3.571.677 -2,68 0,29 -28.481 1.035.786
2012-07-05 2012-07-02 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -80.348 3.669.887 -2,14 0,29 -23.301 1.064.267
2012-07-02 2012-06-28 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -19.500 3.750.235 -0,52 0,29 -5.655 1.087.568
2012-06-21 2012-06-19 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -12.000 3.759.735 -0,32 0,29 -3.480 1.090.323
2012-06-19 2012-06-15 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -1.450 3.781.735 -0,04 0,29 -420 1.096.703
2012-06-07 2012-06-06 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -8.400 3.783.185 -0,22 0,29 -2.436 1.097.124
2012-06-07 2012-06-05 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -29.555 3.791.585 -0,77 0,29 -8.571 1.099.560
2012-06-04 2012-05-31 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -29.850 3.821.140 -0,78 0,30 -8.955 1.146.342
2012-06-04 2012-05-30 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -51.007 3.850.990 -1,31 0,30 -15.302 1.155.297
2012-06-04 2012-05-29 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -15.300 3.901.997 -0,39 0,30 -4.622 1.178.793
2012-06-04 2012-05-25 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -293.015 3.917.297 -6,96 0,30 -87.904 1.175.189
2012-06-04 2012-05-23 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -135.250 4.210.312 -3,11 0,30 -40.629 1.264.778
2012-06-04 2012-05-22 4 SOMX Somaxon Pharmaceuticals, Inc.
Common Stock
S - Sale -287.000 4.345.562 -6,20 0,30 -86.990 1.317.140
2012-03-08 2012-03-06 4 VSTM Verastem, Inc.
Stock Option (Right to Buy)
A - Award 12.500 12.500
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Series C Preferred Stock
C - Conversion -266.666 0 -100,00
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Series B Preferred Stock
C - Conversion -2.500.000 0 -100,00
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Series A Preferred Stock
C - Conversion -4.000.000 0 -100,00
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Common Stock
P - Purchase 3.740 3.740 10,00 37.400 37.400
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Common Stock
P - Purchase 96.260 2.029.593 4,98 10,00 962.600 20.295.930
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Common Stock
C - Conversion 76.190 1.933.333 4,10
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Common Stock
C - Conversion 714.286 1.857.143 62,50
2012-02-03 2012-02-01 4 VSTM Verastem, Inc.
Common Stock
C - Conversion 1.142.857 1.142.857
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)